Sun Biomedical (ASX:SBN) Change In Payables And Accrued Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sun Biomedical Change In Payables And Accrued Expense?

Sun Biomedical's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Sun Biomedical's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Sun Biomedical's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Sun Biomedical's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

Sun Biomedical Change In Payables And Accrued Expense Historical Data

The historical data trend for Sun Biomedical's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical Change In Payables And Accrued Expense Chart

Sun Biomedical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Sun Biomedical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sun Biomedical Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Sun Biomedical Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Biomedical (ASX:SBN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

DXB:Australia

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines